A Phase II Clinical Trial of Neoadjuvant Concurrent Chemoradiotherapy for Locally Advanced High-Grade Thymic Tumors
Neoadjuvant concurrent chemoradiotherapy is well tolerated and effective for patients with potentially unresectable high-grade thymic tumors, especially for patients with thymomas. Effective induction chemoradiation may help increase the chance of surgical resection and prolonged disease control. Future studies are in need to find more effective treatment approaches for patients with thymic carcinomas.
Authors
- Yan Shen (ORCID: https://orcid.org/0000-0001-7058-8602)
- Yu Liu (ORCID: https://orcid.org/0000-0002-7968-0162)
- Wentao Fang (ORCID: https://orcid.org/0000-0002-6517-9975)
- Ning Xu
- Lei Zhu (ORCID: https://orcid.org/0000-0003-1685-7968)
- Qin Zhang (ORCID: https://orcid.org/0000-0002-4597-7697)
- Xuefei Zhang (ORCID: https://orcid.org/0000-0002-1873-6679)
- Zhitao Gu
- Xiuxiu Hao (ORCID: https://orcid.org/0000-0002-1011-2829)
- Teng Mao
- Jianxin Shi
- Lanting Gao
- Changlu Wang
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Chest Hospital (CN)
- Shanghai East Hospital (CN)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100821
- Citations
- 2
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Shanghai Chest Hospital